下载掌阅APP，畅读海量书库
立即打开
［1］MAILLARD N, WYATT R J, JULIAN B A, et al. Current understanding of the role of complement in IgA nephropathy [J]. J Am Soc Nephrol, 2015, 26 (7): 1503-1512.
［2］ESPINOSA M, ORTEGA R, SANCHEZ M, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2014, 9 (5): 897-904.
［3］RICKLIN D, HAJISHENGALLIS G, YANG K, et al. Complement: a key system for immune surveillance and homeostasis [J]. Nat Immunol, 2010, 11 (9): 785-797.
［4］GHARAVI A G, KIRYLUK K, CHOI M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy [J]. Nat Genet, 2011, 43 (4): 321-327.
［5］TORTAJADA A, YEBENES H, ABARRATEGUI G C, et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation [J]. J Clin Invest, 2013, 123 (6): 2434-2446.
［6］HOLMES LV, STRAIN L, STANIFORTH S J, et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32 [J]. PLoS One, 2013, 8 (4): e60352.
［7］XIE J, KIRYLUK K, LI Y, et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese [J]. J Am Soc Nephrol, 2016, 27 (10): 3187-3194.
［8］JULLIEN P, LAURENT B, CLAISSE G, et al. Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy [J]. J Am Soc Nephrol, 2018, 29 (2):661-669.
［9］ZHU L, GUO W Y, SHI S F, et al. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy [J]. Kidney Int, 2018, 94 (1): 150-158.
［10］MEDJERALl-THOMAS N R, LOMAX-BROWNE H J, BECKWITH H, et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy [J]. Kidney Int, 2017, 92 (4): 942-952.
［11］OHSAW A I, ISHII M, OHI H, et al. Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy [J]. J Biomed Biotechnol, 2012, 2012: 476739.
［12］GUO W Y, ZHU L, MENG S J, et al. Mannose-binding lectin levels could predict prognosis in IgA nephropathy [J]. J Am Soc Nephrol, 2017, 28 (11): 3175-3181.
［13］SHIMAMOTO M, OHSAWA I, SUZUKI H, et al. Impact of body mass index on progression of IgA nephropathy among Japanese patients [J]. J Clin Lab Anal, 2015, 29 (5): 353-360.
［14］SUZUKI H, OHSAWA I, KODAMA F, et al. Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy [J]. J Nephrol, 2013, 26 (4): 708-715.
［15］KIM S J, KOO H M, LIM B J, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy [J]. PLoS One, 2012, 7 (7): e40495.
［16］NASRI H, SAJJADIEH S, MARDANI S, et al. Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy [J]. J Nephropathol, 2013, 2 (3): 190-195.
［17］SAHIN O Z, YAVAS H, TASLI F, et al. Prognostic value of glomerular C4d staining in patients with IgA nephritis [J]. Int J Clin Exp Pathol, 2014, 7 (6): 3299-3304.
［18］ROSENBLAD T, REBETZ J, JOHANSSON M, et al. Eculizumab treatment for rescue of renal function in IgA nephropathy [J]. Pediatr Nephrol, 2014, 29 (11): 2225-2228.
［19］RING T, PEDERSEN B B, SALKUS G, et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum [J]. Clin Kidney J, 2015, 8 (5): 489-491.
［20］NAKAMURA H, ANAYAMA M, MAKINO M, et al. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: acase report successfully treated with eculizumab [J]. Nephron, 2018, 138 (4): 324-327.
［21］MATSUMURA D, TANAKA A, NAKAMURA T, et al. Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report [J]. Clin Nephrol Case Stud, 2016, 4: 24-28.
［22］HERZOG A L, WANNER C, AMANN K, et al. First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation: a case report [J]. Transplant Proc, 2017, 49 (7): 1574-1577.